Roche Antiviral Drug Reduces Transmission in Late-stage Study
Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected ...
Pharmabiz5d
Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses
Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses: Basel Friday, September 20, 2024, 09:00 Hrs [IST] Roche announc ...
Yahoo Finance5d
Roche Holding AG (RHO6.SG)
SOUTH SAN FRANCISCO, Calif., September 19, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of ...
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
Roche Holdings AG (OTC:RHHBY) released positive topline results of the phase 3 CENTERSTONE study of Xofluza (baloxavir ...
Bluewin5d
Success for Roche New flu drug reduces risk of infection
Roche has achieved a research success with its flu drug Xofluza. As the latest data from the pivotal Centerstone study show, Xofluza has reduced the transmission of influenza from an infected person ...
The Pharma Letter5d
Roche touts positive Phase III results with Xofluza
Roche today released positive top-line results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an ...
Roche unit hits main goal in late-stage trial for flu therapy
Roche (RHHBF) unit Genentech said Xofluza antiviral reached the main goal in a global Phase 3 trial, reducting the ...
Bluewin6d
Pharmaceuticals Roche achieves research success with flu drug Xofluza
Roche has achieved a research success with its influenza drug Xofluza. As the latest data from the pivotal Centerstone study show, Xofluza has reduced the transmission of influenza from an infected ...
Roche's Xofluza Reduces Influenza Transmission In Phase III Study
Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...
Yahoo Finance6d
Roche reports positive data from Phase III influenza treatment trial
Roche has announced positive topline data from the Phase III CENTERSTONE clinical trial of Xofluza (baloxavir marboxil), an ...
F. Hoffmann-La Roche Ltd: Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is the first time that any antiviral used in the treatment ...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to ...